1. Scrip
  2. >>Business
  3. >>Earnings

Roche Lifts Outlook, Spotlights Perjeta To Drive Growth

 
• By John Davis

A “phenomenal” start by Ocrevus and the use of two other newly launched medicines, Tecentriq and Alecensa, drove sales growth at Roche in the first half of 2017 – with the previously cautious company now upgrading its financial outlook for the year and expecting further growth from breast cancer therapy Perjeta.

Schwan_Severin_1200x675
Severin Schwan, CEO of Roche

The CEO of Switzerland’s big pharma company Roche, Severin Schwan, has categorized the launch of the new multiple sclerosis therapy Ocrevus (ocrelizumab) in the first half of 2017 as “particularly pleasing,” a “phenomenal start,” and “even above our own expectations.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Regulatory And Macroeconomic Uncertainty Hang Over Q1 Earnings Season

 
• By Jessica Merrill

As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.

US Pharma Tariff Reprieve Appears Short-Lived

 
• By Jessica Merrill

Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.

Pharma Exhales, Dodging A Financial Blow With Tariff Exemption

 
• By Jessica Merrill

Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s tariff rollercoaster; regulatory, economic uncertainties hang over Q1 earnings; IPOs rise in Q1 but may slow; Chinese deal-making matures; and AstraZeneca talks about Chinese innovation.

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

 
• By Joseph Haas

Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.

Biotech Leaders Ponder Tariff Ramifications

 
• By Joseph Haas, Mary Jo Laffler, and Jessica Merrill

Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.